Find Experts

Experts in Oncology
Jairaj K. Acharya Thomas P. Fondy Swarnali Acharyya Bachir Alobeid Richard Baer Aneel K Aggarwal Margaret H Baron Benjamin O. Anderson Parveen Bhatti Marita Zoma Chu Chen Eric Chow Giuseppina Carbone Asma Amleh Katia Basso Govind Bhagat Shiuan Chen Casey L. Daniel WenYong Chen Natalie R. Gassman View More
Rodrigo Dienstamann

Principal Investigator
Oncology
Vall d'Hebron Institut d’Oncologia
Spain

Scientist Oncology
Biography

Dr. Rodrigo Dienstamann is currently working as a Principal Investigator, Oncology Data Science (ODysSey) Group in the Department of Oncology, Vall d'Hebron Institute of Oncology , Spain. His research interests includes cancer therapy, genomics, computational oncology. He is serving as an editorial member and reviewer of several international reputed journals. Dr. Rodrigo Dienstamann is the member of many international affiliations. He has successfully completed his Administrative responsibilities. He has authored of many research articles/books related to cancer therapy, genomics, computational oncology.

Research Intrest

Integration of clinical and translational research with genomics for precision cancer therapy Clinical-molecular databases of matched targeted agents and standardized reports of next-generation sequencing tests. Collaborative research in cancer genomics/computational oncology and its clinical implications

List of Publications
Dienstmann R, Lassen U, Cebon J, Desai J, Brown MP, Evers S, Su F, Zhang W, Doisserie F, Lestini B, Schostack K, Meresse V, Tabernero J. First-in-man dose-escalation study of the selective BRAF inhibitor RG7256 in patients with BRAF V600-mutated advanced solid tumors.Target Oncol. 2016;11(2):149-56.
Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Mol Cancer Ther. 2016;15(5):1106-12.
Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espin E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase inhibition blocks Wnt/β-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2016;22(3):644-56.
Experts in Spain
Alba Ruiz de Andrés Beatriz Mothe Ester Ballana Guix Javier Martínez-Picado Julia García Prado Roger Paredes Antonio Cabrales Julià Blanco Antonio Miguel De Ron Pedreira José Esté Marc Noguera i Julian Eva Riveira Maria Casadellà Miguel Ángel Martínez Nuria Izquierdo-Useros Roger Badia Sandra Franco ABASCAL MONEDERO Antonio Ciccone J. Ignacio Conde-Ruiz Javier Ferri Maia Güell Ginés De Rus Dr Elena Arrondo Dr. Eva Ayala View More